Skip to main content

Advertisement

SpringerLink
Log in

Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Objectives: Ovarian cancer has the highest mortality of all the gynecologic cancers. The antitumor agent paclitaxel has been proved to be efficient in the treatment of ovarian cancer. Our study is to develop a polymeric drug delivery system for paclitaxel and determine whether paclitaxel nanoparticle can inhibit growth of ovarian carcinoma xenografts in Fisher344 (F344) rats by intraperitoneal administration. The mechanism of paclitaxel nanoparticles in rats bearing ovarian cancer has been investigated in this study. Methods: Synthesize paclitaxel loading nanoparticle (PLA) by ultrasonic emulsification; MTT analysis identified cytotoxic activity of paclitaxel nanoparticle in vitro; rat ovarian carcinoma cells were injected into the peritoneal cavity of F344 rats. The antitumor effect of paclitaxel nanoparticle in vivo has been evaluated by measuring tumor weight and ascite volume. At the end of the procedure rats were sacrificed; tumors were excised and processed for PCNA staining, tissue terminal deoxynucleotide transferase-mediated dUTP nick and labeling assay and RT-PCR to evaluate the proliferative and apoptotic changes and cancer transfer-related gene expression induced by PLA. Paclitaxel concentration in plasma, pelvic lymph nodes, liver, and heart were determined by high-performance liquid chromatography. Results: Paclitaxel nanoparticle and PTX (Cremophor) showed equivalent cytotoxic activity in vitro. In rats implanted carcinoma cells, paclitaxel nanoparticles significantly reduced tumor weight and ascites volume, and induced apoptosis of tumor cells. PLA also inhibited cell proliferation and matrix metalloproteinase 9 mRNA expression. The paclitaxel concentration of pelvic lymph nodes in PLA treated animals was 20-fold higher than that of free PTX treated animals at 48 h after intraperitoneal administration. Conclusion: The intraperitoneal administration of paclitaxel nanoparticle can significantly inhibit the progression of ovarian carcinoma in peritoneal cavity of female F344 rat. The paclitaxel nanoparticle is safe and lymphatic targeting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Ozols R (1999) Treatment of gynecologic cancer: the US experience. Tumori 85:S5–S11

    Article  PubMed  CAS  Google Scholar 

  2. Gelderblom H, Verweij J, Nooter K, et al (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598

    Article  PubMed  CAS  Google Scholar 

  3. Klooer JS, den Bakker MA, Gelderbolm H, et al (2004) Fatal outcome of a hypersensitivity reactions to paclitaxel: a critical review of premedication regimens. Br J Cancer 90:304–305

    Article  PubMed  Google Scholar 

  4. Wang YM, Sator H, Dachi I, et al (1996) Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of novel anticancer agent, taxol. Chem Pharm Bull (Tokyo) 44:1935–1940

    CAS  Google Scholar 

  5. Alex S, Charity DS, Vuong T, et al (2005) Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle Albumin-bound paclitaxel (ABI007) and paclitaxel formulated in Cremophor (taxol). Clin Cancer Res 11:4236–4143

    Google Scholar 

  6. Dedrick RL, Myers CE, Bungay PM, et al (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11

    PubMed  CAS  Google Scholar 

  7. Philippe M, Pierre T, Claude A, et al (1992) Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res 9:1534–1539

    Article  PubMed  Google Scholar 

  8. Markman M, Rowinsky E, Hakes T, et al (1992) Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 10:1485–1491

    PubMed  CAS  Google Scholar 

  9. Francis P, Rowinsky E, Schneider J, et al (1995) Phase feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 13:2961–2967

    PubMed  CAS  Google Scholar 

  10. Yun M, Lee YL (2005) Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Release 107:30–42

    Article  PubMed  CAS  Google Scholar 

  11. Fonseca C, Simoes S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physiochemical characterization and in vitro anti-tumoral activity. J Control Release 83:273–286

    Article  PubMed  CAS  Google Scholar 

  12. Mu L, Feng SS (2002) Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (taxol). J Control Release 80:129–144

    Article  PubMed  CAS  Google Scholar 

  13. Joanna MK, Paul RL, David DA, et al (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 99:259–269

    Article  PubMed  CAS  Google Scholar 

  14. Hamaguchi T, Matsumura Y, et al (2005) NK105, a paclitaxel-incorporation micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92:1240–1246

    Article  PubMed  CAS  Google Scholar 

  15. Olin T, Saldeen T (1964) The lymphatic pathways from the peritoneal cavity: a lymphangiographic study in the rat. Cancer Res 24:1700–1711

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China

    Hongxia Lu, Bin Li, Yu Kang, Wei Jiang, Qian Huang & Congjian Xu

  2. Shanghai Institute of Pharmaceutical Industry, Shanghai, 200040, China

    Qinghua Chen & Limin Li

Authors
  1. Hongxia Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qian Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qinghua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Limin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Congjian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Qinghua Chen or Congjian Xu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, H., Li, B., Kang, Y. et al. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol 59, 175–181 (2007). https://doi.org/10.1007/s00280-006-0256-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0256-z

Keywords

Search

Navigation